Diabetic Retinopathy Market Report

Global Diabetic Retinopathy Market Size

The Global Diabetic Retinopathy Market is projected to grow from USD 9.10 billion in 2025 to USD 9.72 billion in 2026 and reach USD 16.58 billion by 2034, registering a CAGR of 6.9% from 2026 to 2034.

It is a medical complication that affects the retina in the eye in diabetic patients. It impacts the blood vessels in the eye, which may lead to vision loss and blindness. Therefore, patients must undergo an eye examination test like a Visual acuity test, Pupil dilation, Ophthalmoscopy or fundus photography, Fundus Fluorescein angiography (FFA), Retinal vessel analysis, or Optical coherence tomography (OCT) to confirm the disease. As per the National Center for Biotechnology Information, the populace affected with Diabetic Retinopathy (DR) was 126 million in 2010. This value will reach 191 million by the end of 2030, which will influence the growth of the diabetic retinopathy market at an equal pace.

MARKET DRIVERS

YOY growth in the patient count who has diabetes, an increasing number of product launches, increasing strategic developments such as partnerships and agreements between the market participants, and favorable research funding scenarios propel the diabetic retinopathy market growth.

According to the findings of the International Diabetes Federation (IDF), an estimated 537 million people worldwide had diabetes in 2023, and this figure is anticipated to reach 643 million by 2030 and 783 million by 2045. Currently, an estimated 541 million people worldwide higher risk of developing type 2 diabetes soon. According to the Centers for Disease Prevention and Control (CDC), an estimated 11.3% of the population of the United States has diabetes. Rising incidences of diabetes, the inability to cope with the retinal screening of patients with diabetes, and growth in the awareness among people over the diagnosis and treatment services in hospitals are driving the global diabetic retinopathy market growth. Diabetic Retinopathy affects over 33% of diabetes patients and is the principal cause of blindness in the 20-79 aged population with diabetes. India, China, and Bangladesh represent over 40% of the global diabetic retinopathy burden. In Africa, two-thirds of people with diabetes remain undiagnosed. About 30% of people with Diabetic Retinopathy present the greatest unmet need. In the United States, Diabetic Retinopathy is the leading cause of new cases of legal blindness among adults aged 20 to 79.

In addition, increasing demand for continuous monitoring of diseases, rising capital income in developed and developing countries, and growing geriatric population further fuel market growth. Rising demand for cost-effective and protective treatment procedures and having the least quality diagnosis are estimated to favor the global diabetic retinopathy market growth.

MARKET RESTRAINTS

Less knowledge about the treatment options, shortage of skilled ophthalmologists, and strict government rules are major restraints to the market growth. Diabetic Retinopathy is a common diabetic eye disease; that leads to eye blindness for diabetic patients. The lack of trained or technically skilled professionals is the major restraint of the diabetic retinopathy market. Further, the major drawback of the diabetic retinopathy market was the costliest treatment. The availability of advanced technology and various treatment methods like laser treatment is hindering the market. Moreover, prescribing medication to decrease the impact of diabetic retinopathy will be a significant drawback for the market. In addition, the lengthy approval times for drugs and lack of awareness about diabetic retinopathy treatment in emerging countries like India, South Africa, etc., will affect the market growth.

REPORT COVERAGE
 

SEGMENTAL ANALYSIS

By Treatment Type Insights

 The Anti-vascular endothelial growth factor (VEGF) segment led the market in 2025 and is predicted to showcase domination in the global diabetic retinopathy market during the forecast period.On the other hand, the laser surgery segment is expected to showcase a healthy CAGR during the forecast period. The laser treatment is further divided into focal laser treatment and scatter laser treatment. The focal laser treatment is growing tremendously with the rise in the prevalence of early diagnosis. In addition, the availability of skilled physicians to manage health disorders and increasing support from the government through investments are promoting the segment's growth rate.

By Indication Insights

The non-proliferative diabetic retinopathy segment dominated the market and is predicted to continue dominating throughout the forecast period. Ongoing research in developing innovative procedures for diagnosing various diseases and increasing the scale of specialty care centers favors segmental growth.On the other hand, the proliferative diabetic retinopathy segment is expected to witness the fastest CAGR during the forecast period.

By End-User Insights

The hospitals segment accounted for the major share of the market in 2023. The segment’s dominance is expected to continue in the coming years owing to the rise in the construction activities of hospitals with the latest equipment. If diabetes is untreated properly, it may damage blood vessels in the retina of an eye. Therefore, increasing expenditure on healthcare is further driving the segment's growth.

REGIONAL ANALYSIS

Geographically, the North American diabetic retinopathy market held the most significant share of the global market in 2025, and the region’s dominance is anticipated to continue during the forecast period. The growing incidence of diabetes is one of the major factors propelling the market growth in North America. According to the statistics published by World Health Organization (WHO), the prevalence of diabetes was 14.3% in the U.S. and 9% in Canada in 2019. Furthermore, the patient count who has diabetes in North American countries is growing considerably with each year passing, which is estimated to promote the growth of the diabetic retinopathy market in this region.

The European diabetic retinopathy market accounted for the second-largest global market share in 2025. Europe has a large population of baby boomers, which favors the market growth in Europe. Diabetic retinopathy is one of the significant health burdens in the European region. A considerable diabetic population in the European region has suffered vision loss in recent years. WHO says the prevalence of diabetes was 8.5% in 2019 and is expected to increase to 25% by the end of the next decade of the timeline. UK and Germany are anticipated to witness a healthy CAGR from Europe during the forecast period due to the high incidence rate of diabetes in these countries.

The Asia-Pacific diabetic retinopathy market is estimated to grow at the highest CAGR. The growing population of diabetes and the local people's changing lifestyles are primary factors boosting the market in the Asia Pacific. The growing number of people with diabetes in this region primarily drives the growth of the Asia-Pacific diabetic retinopathy market. In addition, emerging economies such as Japan and China in the Asia-Pacific region will grow significantly during the forecast period due to rising disposable income, a growing elderly population, increased funding for diabetes research, and innovation in diagnostics. The Chinese market is increasing at a healthy rate, whereas Japan is the largest in Asia-Pacific due to high medical expenses and increasing disposable income.

The Latin American diabetic retinopathy market is anticipated to hold a considerable share of the global market during the forecast period. As per World Health Organization (WHO), the prevalence of diabetes in Latin America was 8.7% in 2019 and is expected to increase in the coming years. Countries such as Mexico and Brazil have a higher rate of diabetes incidence in this region.

The Diabetic retinopathy market in MEA is expected to register a moderate share of the global market in the coming years.

KEY MARKET PLAYERS

Some of the notable companies dominating the global diabetic retinopathy market profiled in this report are Bayer Healthcare, Pfizer, Inc., Hoffmann-La Roche Ltd, Regeneron Pharmaceutical, Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science, Inc., and Ampio Pharmaceuticals Inc.

MARKET SEGMENTATION

This research report on the global diabetic retinopathy market has been segmented and sub-segmented based on the treatment type, indication, end-user, and region.

By Treatment Type

• Anti-Vascular Endothelial Growth Factor (VEGF) drug

• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy 

 By Indication

• Non-Proliferative Diabetic Retinopathy (NPDR)
  • Mild
  • Moderate
  • Severe
• Proliferative Diabetic Retinopathy (PDR) 

By End-User

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers

 By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa